March 27, 2024, in the morning, at the AcroImmune innovative large molecule drug R&D center, Lin Tao held detailed discussions with senior executives of AcroImmune Biopharmaceutical Co., Ltd., inquiring about the company’s development history and basic situation. Lin Tao expressed hopes that the center would actively seize global opportunities in the biopharmaceutical industry, accelerate the development of major innovative drugs, develop more economically viable and effective major innovative drugs, and achieve local industrialization within Jiangning District.
Source: Jiangning published
